Issue Price
₹741
Per Share
GMP
NIL
Grey Market
Est. Listing
₹741
Expected Price
Min. Application
₹29,640
2 lots × 20 shares
Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company. The company is ranked among the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in 2022.Concord Biotech has a Global presence. They are supplying their products to over 70 countries including the USA, India, Europe, and Japan.The company manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. It started with a single product and has grown to become a wide-spectrum solution provider.Concord manufactures fermentation and semi-synthetic-based products in therapeutic segments such as Immunosuppressants, Anti-bacterial, Oncology, Antifungals & others. This wide range of products has attracted customers across the globe. Concord also has a robust pipeline of products under development.
Concord Biotech Ltd. proposes to utilise the net proceeds from the Issue for the following objects:
| Category | Shares Offered | % Issue | Amount (₹ Cr)* | Subscription |
|---|---|---|---|---|
| TOTAL | 20,925,652 | 100.00% | ₹1,550.59 Cr | — |
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 20 | ₹14,820 |
| Retail (Max) | 13 | 260 | ₹192,660 |
| sNII (Min) | 14 | 280 | ₹207,480 |
| bNII (Min) | 68 | 1,360 | ₹1,007,760 |
| Particulars | 31 Mar 2021 | 31 Mar 2022 | 31 Mar 2023 |
|---|---|---|---|
| Revenue from Operations | 630.75 | 736.35 | 888.48 |
| EBITDA | N/A | N/A | N/A |
| Profit After Tax (PAT) | 234.89 | 174.93 | 240.08 |
| Net Worth | 999.37 | 1103.22 | 1290.00 |
| Total Assets | 1182.55 | 1312.80 | 1513.98 |
| Reserves & Surplus | N/A | N/A | N/A |
| Total Borrowings | 86.35 | 60.59 | 31.24 |